Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 9/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 7/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20219389 | 1.00 | TLR8 (0.43) | TLR8TLR7KCNH2 | |
| SCHEMBL15470290 | 0.94 | TLR8 (0.42) | TLR8TLR7KCNH2 | |
| SCHEMBL20386695 | 0.94 | TLR8 (0.42) | TLR8TLR7KCNH2 | |
| SCHEMBL20219748 | 0.94 | KCNH2 (0.46) | TLR8TLR7KCNH2 | |
| SCHEMBL13195042 | 0.94 | KCNH2 (0.46) | TLR8TLR7KCNH2 | |
| SCHEMBL23472246 | 0.92 | KCNH2 (0.36) | TLR8TLR7KCNH2 | |
| SCHEMBL20413271 | 0.90 | TLR8 (0.36) | TLR8TLR7KCNH2 | |
| SCHEMBL15470318 | 0.88 | KCNH2 (0.45) | TLR8TLR7KCNH2 | |
| SCHEMBL15469723 | 0.87 | TLR7 (0.36) | TLR8TLR7KCNH2 | |
| SCHEMBL20219542 | 0.85 | TLR8 (0.43) | TLR8TLR7KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11541050-B2 | Pyrimidine derivatives for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2023-01-03 | — | — | US | disclosed |
| EP-3590928-B1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2021-06-09 | — | — | EP | disclosed |
| US-20210023082-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2021-01-28 | — | — | US | disclosed |
| US-10780089-B2 | Pyrimidine derivatives for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2020-09-22 | — | — | US | disclosed |
| US-20200061059-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2020-02-27 | — | — | US | disclosed |
| US-10420767-B2 | Pyrimidine derivatives for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2019-09-24 | — | — | US | disclosed |
| US-10272085-B2 | Pyrimidine derivatives for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2019-04-30 | — | — | US | disclosed |
| US-20180207155-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2018-07-26 | — | — | US | disclosed |
| US-20180207155-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2018-07-26 | — | — | US | disclosed |
| EP-2694484-B1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2018-07-18 | — | — | EP | disclosed |
| US-20170239245-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-08-24 | — | — | US | disclosed |
| US-20170239245-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-08-24 | — | — | US | disclosed |
| US-9422250-B2 | Pyrimidine derivatives for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2016-08-23 | — | — | US | disclosed |
| US-9422250-B2 | Pyrimidine derivatives for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2016-08-23 | — | — | US | disclosed |
| US-20140045849-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2014-02-13 | — | — | US | disclosed |
| US-20140045849-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2014-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10780089-B2 | Pyrimidine derivatives for the treatment of viral infections | TYMP, UMPS, HPRT1 | TLR8 1540/4885TLR7 1000/4885KCNH2 4679/4885 |
| US-20200061059-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | TYMP, UMPS, HPRT1 | TLR8 1540/4885TLR7 1000/4885KCNH2 4679/4885 |
| US-10420767-B2 | Pyrimidine derivatives for the treatment of viral infections | TYMP, UMPS, HPRT1 | TLR8 1540/4885TLR7 1000/4885KCNH2 4679/4885 |
| US-20140045849-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | TYMP, UMPS, HPRT1 | TLR8 1540/4885TLR7 1000/4885KCNH2 4679/4885 |
| US-10272085-B2 | Pyrimidine derivatives for the treatment of viral infections | TYMP, UMPS, HPRT1 | TLR8 1540/4885TLR7 1000/4885KCNH2 4679/4885 |
| US-11541050-B2 | Pyrimidine derivatives for the treatment of viral infections | TYMP, UMPS, HPRT1 | TLR8 1540/4885TLR7 1000/4885KCNH2 4679/4885 |
| US-20210023082-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | TYMP, UMPS, HPRT1 | TLR8 1540/4885TLR7 1000/4885KCNH2 4679/4885 |
| US-20180207155-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | TYMP, UMPS, HPRT1 | TLR8 1540/4885TLR7 1000/4885KCNH2 4679/4885 |
| US-20170239245-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | TYMP, UMPS, HPRT1 | TLR8 1540/4885TLR7 1000/4885KCNH2 4679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.